|Publication number||US3639213 A|
|Publication date||Feb 1, 1972|
|Filing date||Dec 2, 1969|
|Priority date||Dec 2, 1969|
|Also published as||CA976101A1, DE2059165A1|
|Publication number||US 3639213 A, US 3639213A, US-A-3639213, US3639213 A, US3639213A|
|Inventors||Ginger Leonard George, Mather Adaline Nicoles|
|Original Assignee||Baxter Laboratories Inc|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (3), Non-Patent Citations (2), Referenced by (21), Classifications (11)|
|External Links: USPTO, USPTO Assignment, Espacenet|
O United States Patent [151 3,639,213 Ginger et al. Feb. 1, 1972  STREPTOKINASE CHEMICALLY 3,255,094 6/1966 Mather et al 195/66 BONDED To A CARBOHYDRATE FOREIGN PATENTS OR APPLIC TIO MATRIX A n lnvemorsz Leonard George g Genview; 1,577,571 8/1969 France ..l95/63 Adaline Nicoles Mather, Evanston, both of ()TH R PUBLICATIONS lll. Axen et al., Nature, April 23, 1966 pages 367- 369 Asslgneei Baxter Laboratories, Morton Grove, Silman et al., Annual Review of Biochemistry Vol. 35 pages 873- 907 (pages 373- 886 relied on), 1966 Part 11. d: 1  me Dec 969 Primary Examiner-Lionel M. Shapiro  Appl. N0.: 881,632 Attorney-Walter C. Kehm and W. Garrettson Ellis  US. Cl ..195/63, 195/68, 424/94,
195 IDIG H  ABSTRACT  Int. Cl ..C07g 7/02, A6 1 k 19/00 One part by weight of streptokinase is chemically bonded to 1  Field of Search ..l95/63 P, 68, 66 B to 500 parts by weight of a carbohydrate, to form a material which has improved stability compared with free  References Cited streptokinase.
UNITED STATES PATENTS 16 Claims, No Drawings STREPTOKINASE CHEMICALLY BONDED TO A CARBOHYDRATE MATRIX Streptokinase is effective to dissolve various types of blood clots both within and outside of the body. However, a number of difficulties are encountered in the use of the enzyme in therapeutic treatment. Antibodies against streptokinase are present in the blood of essentially all human beings, but the antibody level or titer varies widely among individuals. in order for treatment with streptokinase to be effective, the blood of each patient must be titrated to determine the proper initial dose of enzyme sufficient to nullify the antibodies present in the blood and to provide the proper level of streptokinase enzyme to function as desired, while avoiding the deleterious effects of an excessive dose of streptokinase.
Further, during treatment, the patient develops an increased concentration of antibodies to the enzyme. Hence, a subsequent treatment with streptokinase at a later date may require an increased streptokinase dosage. Also, a subsequent dose may be dangerous since the patient can become sensitized to the enzyme, and may thus undergo a severe allergic reaction.
Additionally, doses of the enzyme must be adequate in the first place in order to effectively dissolve blood clots, and they must be administered repeatedly or continuously, generally by intravenous drip, since the enzyme is metabolized by the body in a relatively short period of time.
Accordingly, there is a need for a substance having a streptokinaselike activity, yet which has increased stability in the body and which also is less subject to neutralization by the antibodies present in the blood stream to make possible a reduction in the amount and frequency of the dosage. Along with such reduced dosages, the danger of allergic reaction and other side effects is reduced.
DESCRIPTION OF THE INVENTION The composition of this application comprises 1 part by weight of streptokinase, chemically bonded to from 1 to 500 parts by weight of a carbohydrate support medium. This material exhibits a streptokinaselike clot dissolving activity, yet it has improved stability in the blood stream, and is less subject to inactivation by blood antibodies than is free streptokinase. Because of this fact, it becomes frequently unnecessary to titrate the individual patients blood, so that a standardized dose can be more easily utilized to achieve the dissolution of blood clots, emboli and the like.
Preferably, streptokinase is covalently bonded to the carbohydrate support medium with from l to 200 parts of the support medium being present for each part by weight of streptokinase. It is also preferred for the carbohydrate support medium used to be water dispersible or water soluble so that the chemically bonded product is able to form colloidal solutions having a particle size of less than about 2 microns. Such colloidal solutions of streptokinase chemically bonded to a carbohydrate can be directly injected, and can circulate freely in the blood without causing serious side effects due to blockage of capillaries and small blood vessels. In this manner, the chemically bonded streptokinase is brought into contact with the clot to act on it.
streptokinase is produced by many strains of hemolytic streptococci, including those of Group A and Lancefield Group C streptococci. The selected streptococci can be conventionally cultured, and the crude streptokinase isolated in a conventional manner. Pyrogenic materials can be removed from the streptokinase preparation, for example, by utilizing the teachings of the Mather et al. US. Pat. No. 3,255,094.
The support media used herein may constitute carbohydrates such as cellulose, dextran, starch, dextrins, or other polysaccharides, preferably having a molecular weight of about 70,000 to about 500,000. Carbohydrate derivatives are also included in the term carbohydrate, including alkali metal containing derivatives, carbohydrate-containing polymers such as copolymcrs of sucrose and epichlorohydrin,
carbohydrates etherified with aminoalkyl groups such as aminoethyl, and carboxyl-containing derivatives such as carboxyethylcellulose, carboxymethyldexltran, and other carboxyalkylcarbohydrates such as carboxypropyldextran and the like. Typically, the carbohydrate support media are chemically modified to provide bonding sites for the streptokinase enzyme.
A carbohydrate support medium having pending carboxylic acid groups, such as the carboxyalkylcarbohydrates, can be converted to an azide in the manner typified in example I below. The azide is then reacted directly with streptokinase, generally at a low temperature between about 0 C. and 10 C., to yield a covalently bonded addu-ct of streptokinase and the carbohydrate support medium of the formula in which R is the carbohydrate support medium having a bond on an oxygen atom thereof connected to the moiety within the brackets, R is said streptokinase having a bond connected to the moiety, typically on an amino nitrogen or a sulfhydryl sulfur atom of the streptokinase, referring to the condition of the atom of the streptokinase prior to reaction with the moiety, and n is a positive integer, preferably 1 or 2.
Another technique for producing a chemical bond between a carbohydrate support medium having pendant carboxylic acid groups and streptokinase is to add a diorganocarbodiimide to a mixture of the support medium and streptokinase in the manner exemplified by examples 4, 5, and 6, to yield a product in which carbonyl groups of the support mediums carboxylic acid groups are directly bonded to the streptokinase, typically to amine nitrogen atoms thereof.
Carbohydrate support media can be covalently bonded to streptokinase as illustrated in example 3 by the use of a triazine of the formula to covalently bond streptokinase to a carbohydrate through a moiety of the formula shown within the brackets in which R and R are as defined above, and X is a halogen, hydrogen, or monovalent hydrocarbon radical of no more than about four carbon atoms. When X is a halogen, it also can be replaced with R or R' group.
Likewise, carbohydrate support media can be chemically bonded to streptokinase by means of cyanogen bromide as shown in example 6. The activation reaction is generally run under alkaline conditions, e.g., a pH of at least 7.5 and preferably above 1 I.
The compositions of this invention can be used to dissolve blood clots and the like by direct administration of a colloidal solution to the clot site, or by passing blood, plasma, or the like through a bed of an insoluble composition of this invention. In this latter circumstance, it is generally preferred to use larger particle sizes, generally in the visible range. An extracorporial circuit can be arranged by loosely packing a particulate composition of this invention into a cartridge, in which blood plasma, whole blood, or another solution passes through tubing into one end of the cartridge, through the par ticulate composition of the invention, and out of the particulate composition, generally past a filter and through an exit tubing. If desired, the blood or other fluid can be directly withdrawn from a subject and/or then administered to the subject after treatment.
Similarly, conventional reaction columns containing the material of this invention can be used, or the material of this invention can be impregnated in a matrix such as silicone rubber and incorporated in tubing through which the material to be treated passes.
The following examples are offered for illustrative purposes only, and are not intended to limit the scope of the invention.
EXAMPLE 1 Ten grams of the sodium salt of carboxymethyl dextran having a weight average molecular weight of about 100,000, 15 ml. of concentrated hydrochloric acid, and 250 ml. of methanol are heated at reflux for 4 hours. The solvent is removed by vacuum distillation, and the residue suspended in 50 ml. of methanol. A 20 percent solution of hydrazine in methanol is added and stirred until no more white precipitate is formed. The precipitate is then stirred for four hours, filtered and dried. Five grams of the precipitated product are then resuspended in 150 ml. of 2 percent hydrochloric acid, and cooled to between and 5 C. An excess of dilute nitrous acid solution is added slowly with constant stirring.
The resulting product is precipitated and washed with methanol. The precipitate consists largely of dextran having units linked to oxygen atoms of the dextran, the material being informally called dextran azide.
After careful washing, the dextran azide is redissolved in a water solution of about 0.05 to 0.1M disodium phosphate and 0.9 weight percent sodium chloride, adjusted to about pH 7.0. The concentration of dextran azide is adjusted to about 25 to 50 mg. per ml. of the phosphate-saline buffered solution.
Purified streptokinase is then dissolved in the above solution at a level of about 100,000 enzyme units per ml. of solution, and allowed to stand for about 12 hours (the enzyme units being as defined by the National Institutes of Health).
The resulting mixture is then passed through a molecular sieve comprising a material such as the cross-linked dextran sold under the name Sephadex 150 or Sephadex 200, or the commercially available material Biogel P, which is a crosslinked polyacrylamide.
The resulting filtrate is a solution containing dextran which is covalently bonded to streptokinase by a linkage or moiety shown within the brackets of the formula 0 niomlig rn' in which R is dextran, bonded to the linkage through an oxygen atom of the dextran,and R is the streptokinase connected to the linkage. It is believed that the major portion of the linkages to the streptokinase are connected thereto through amine nitrogen atoms of the streptokinase. The free streptokinase is absorbed by the molecular sieve, and can be removed by further washing.
The resulting product exhibits the capability of dissolving blood clots and the like, while also showing growing greater stability at ambient and warm temperatures when compared with free streptokinase.
Alternatively, free streptokinase can be separated from the covalently bonded dextran-streptokinase composition by precipitation of thefree streptokinase with ammonium sulfate, and then removing of the precipitate by filtering or centrifuging. Excess salt and other ionic materials can be removed'from the dextrau-streptokinase solution by dialysis or in any other conventional manner.
EXAMPLE 2 Equivalent results are obtained when the experiment of example l is repeated using carboxyethyldextran having a weight average molecular weight of about 300,000 in substitution for the sodium salt of carboxymethyldextran.
Furthermore, after the dextran azide is prepared from the above and filtered, good results are obtained by dissolving the dextran azide prepared above to saturation in a 0.05 M solution of tris-(hydroxymethyl )aminomethane buffer having a pH of approximately 8.0 with the purified streptokinase being then placed into the solution and allowed to stand with stirring for about 16 hours.
EXAMPLE 3 A. Dextran having a molecular weight of about 200,000 is dissolved in a saturated solution of sodium bicarbonate. Cyanuric chloride is then added in such a concentration as to provide about one mole of cyanuric chloride for each mole ofON a group present upon the dextran. The mixture is then stirred for about 1 hour at room temperature, filtered to remove any insoluble material, and dialyzed against saturated sodium bicarbonate to remove any unreacted cyanuric chloride.
Purified streptokinase is added to provide about 100,000 enzyme units (as defined above) per ml. of solution containing the dissolved cyanuric chloride-dextran reaction product, and the mixture is allowed to react for about 14 hours at 5 C. Any remaining free streptokinase is separated from the resulting covalently bonded dextran-streptokinase by passing the material through a molecular sieve or by precipitation of the free streptokinase with ammonium sulfate.
The resulting material exhibits blood clot dissolving activity, and has increased stability with respect to free streptokinase.
B. Generally equivalent results to the above are obtained when the dextran is replaced with a sucrose-containing polymer (Ficoll, a copolymer of sucrose and epichlorohydrin, manufactured by Pharmacia of Uppsala, Sweden) having a weight average molecular weight of 400,000, or when cyanuric chloride is replaced with any of compounds A through G below, each of the formula in which X represents the respective radicals shown below:
bromide methyl hydrogen isopropyl n-butyl iodide allyl EXAMPLE 4 Approximately 30 to 50 mg. of carboxymethyl cellulose are weighed into a 25 ml. Erlenmeyer Flask. Dilute hydrochloric acid is added in a dropwise manner to adjust the pH to between 4 and 5. From 3 to 5mg. of dicyclohexylcarbodii- Compound A mide, and 0.2 to 0.5 mole of tetrahydrofuran (as solubilizing in which R is cellulose bonded to the linkage through a free oxygen atom of the cellulose, and R is streptokinase bonded to the linkage. It is believed that the major portion of the linkages to the streptokinase are connected thereto through amine nitrogen atoms of the streptokinase. The product shows clot decomposing activity.
Equivalent results to the above are obtained when carboxymethyl-cellulose is replaced with a carboxymethylated copolymer or sucrose and epichlorohydrin having a weight average molecular weight of about 400,000.
EXAMPLE 5 Generally equivalent results to those obtained in example 4 I are obtained upon substitution of dicyclohexylcarbodiimide by either l-cyclohexyl-3-(2-morpholinyl)-4-ethylcarbodiimide methyl-p-toluene-sulfonate or 4- morpholinodimethylaminopropylcarbodiimide, in the absence of tetrahydrofuran.
EXAMPLE 6 EXAMPLE 7 Two grams of cyanogen bromide are dissolved in 50 ml. of distilled water adjusted to a pH of l 1.5 by addition of aqueous sodium hydroxide solution. Two grams of dextran having a weight average molecular weight of 500,000 are added, and the suspension is magnetically stirred for approximately 30 minutes. The dextran is precipitated by addition of 50 percent ethyl alcohol, centrifuged, and washed with absolute ethanol. Excess ethanol is removed under vacuum.
Five hundred mg. of the resulting material, the structure of which is uncertain at the present time are dissolved in 5 ml. of 0.10 M sodium phosphate buffer, pH 7.5, and 5 mg. of streptokinase are added. The mixture is stirred for sixteen hours while the temperature is maintained at 4 C.
The resulting material comprises dextran chemically bonded to streptokinase, and has streptokinase clot dissolving activity.
Equivalent results are obtained upon substituting a commercially available copolymer of sucrose and epichlorohydrin for dextran in this experiment.
What is claimed is:
l. A composition of matter which comprises one part by weight of streptokinase, covalently bonded to from l to 500 parts by weight of a dextran support medium having a molecular weight of about 70,000 to 500,000, said composition of matter being capable of forming colloidal solutions having a particular size ofless than about 2 microns.
2. The composition of claim 1 in which said dextran support medium is modified with carboxyalkyl groups.
3. The composition of claim 1 in which from 10 to 200 parts by weight of said dextran support medium are present per part by weight of streptokinase.
4. The composition of claim 1 in which said streptokinase is bonded to a dextran support medium by at least one moiety shown within the brackets of the formula in which R is said dextran support medium having a bond on an oxygen atom thereof connected to said moiety, R is said streptokinase having a bond connected to said moiety on an atom thereof and n is a positive integer.
5. The composition of claim 4 in which from l0 to 200 parts by weight of said support medium are present per part by weight of streptokinase.
6. The composition ofclaim 5 in which n has a value of one to two.
7. the composition of claim 6 in which said support medium is a carboxylakyl dextran.
8. The composition of claim 1 in which said streptokinase is bonded to a dextran support medium by at least one moiety shown within the brackets of the formula I N- o R-C N in which R is said dextran support medium having a bond connected to said moiety on an oxygen atom thereof, R is said streptokinase having a bond connected to said moiety, and X is selected from the group consisting of monovalent hydrocarbon radicals of no more than 4 carbon atoms, hydrogen, halogen atoms, and R and R groups.
9. The composition of claim 8 in which from 10 to 200 parts by weight of said dextran support medium are present per part by weight of streptokinase.
10. The composition ofclaim 9 in which X is chlorine.
11. The process of contacting a dextran with cyanogen bromide under alkaline conditions to form a reaction product therebetween, and thereafter contacting one part by weight of streptokinase with from 1 to 500 parts by weight of said reaction product to form a chemically bonded water soluble adduct comprising said dextran and streptokinase.
12. The chemically bonded adduct prepared by the process of claim ll.
13. The composition of claim 12 produced by contacting from 10 to 200 parts by weight of said reaction product with one part by weight of streptokinase.
14. The composition of claim 13 in which said alkaline conditions used for preparing said reaction product constitute a pH of at least ll.
15. The process of contacting from I to 500 parts by weight of a dextran, having pendant groups of the formula bonded to oxygen atoms of said carbohydrate, with one part by weight of streptokinase to form a water soluble covalently bonded adduct of said dextran and streptokinase, in which n is a positive integer.
16. The process of contacting (1) from 1 to 500 parts by weight of the reaction product of a dextran and a compound of the formula in which X is selected from the group consisting of halogen, hydrogen, and monovalent hydrocarbon radicals of no more than 4 carbon atoms with (2) one part by weight of streptokinase to form a water soluble covalently bonded adduct of said dextran and streptokinase.
UNITED STATES PATENT OFFTQE CERTIFICATE OF CoRREoiN 3,633213 I Dated February 1, 1972 Patent No.
Invent0r(s) Leonard George Gi 31 It is certified that error appears in the above-identified patent and that said Letters Patentare hereby corrected as shown below:
Column 5, line 62,. "particular" should read particle Signed and sealed this 24th day of October 1972.
- (SEAL) Attest:
EDWARD M.FLETCHER,JR. 7 ROBERT GOTTSCHALK Attesting Officer Commissioner of Patents 'ORM P0-105O (10-69) USCOMM-DC 60376-P69 U5. GOVERNMENT PRINTING OFFICE: I969 O366-33
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US3186920 *||Feb 7, 1963||Jun 1, 1965||Behringwerke Ag||Process for preparing a streptokinase|
|US3255094 *||Jan 10, 1963||Jun 7, 1966||Baxter Laboratories Inc||Method for purification of streptokinase|
|FR1577571A *||Title not available|
|1||*||Axen et al., Nature, April 23, 1966 pages 367 369|
|2||*||Silman et al., Annual Review of Biochemistry Vol. 35 pages 873 907 (pages 873 886 relied on), 1966 Part II.|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US3865615 *||May 7, 1973||Feb 11, 1975||Air Prod & Chem||Non-thrombogenic plastics|
|US4055635 *||Jul 2, 1974||Oct 25, 1977||Beecham Group Limited||Fibrinolytic compositions|
|US4167446 *||Oct 30, 1975||Sep 11, 1979||Bayer Aktiengesellschaft||Water soluble carrier-bound penicillinacylase|
|US4179337 *||Jul 28, 1977||Dec 18, 1979||Davis Frank F||Non-immunogenic polypeptides|
|US4273873 *||Oct 25, 1977||Jun 16, 1981||Unitika Ltd.||Preparation of antithrombogenic polymeric materials|
|US4305926 *||Sep 13, 1979||Dec 15, 1981||Johannes Everse||Immobilization of Streptokinase|
|US4409138 *||Sep 5, 1980||Oct 11, 1983||Etablissement Texcontor||Non-absorbable compounds of mucolytic activity, the process for their preparation, and therapeutic compositions which contain them as active principle|
|US4474756 *||Jan 4, 1982||Oct 2, 1984||Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo||Process for the production of anti-human protein antibody|
|US4559322 *||Jul 11, 1983||Dec 17, 1985||Etablissement Texcontor||Non-absorbable compounds of mucolytic activity, the process for their preparation, and therapeutic compositions which contain them as active principle|
|US5133968 *||Aug 20, 1990||Jul 28, 1992||Kanebo, Ltd.||Modified protease, method of producing the same and cosmetic products containing the modified protease|
|US5230891 *||Apr 22, 1992||Jul 27, 1993||Kanebo Limited||Modified protease, method of producing the same and cosmetic products containing the modified protease|
|US5382657 *||Aug 26, 1992||Jan 17, 1995||Hoffmann-La Roche Inc.||Peg-interferon conjugates|
|US5539063 *||Jun 1, 1995||Jul 23, 1996||Hoffmann-La Roche Inc.||Polymer for making poly(ethylene glycol)-protein conjugates|
|US5559213 *||Jun 1, 1995||Sep 24, 1996||Hoffmann-La Roche Inc.||Polyethylene-protein conjugates|
|US5595732 *||Sep 27, 1991||Jan 21, 1997||Hoffmann-La Roche Inc.||Polyethylene-protein conjugates|
|US5747646 *||Jun 1, 1995||May 5, 1998||Hoffmann-La Roche Inc.||Polyethylene-protein conjugates|
|US5792834 *||Jun 1, 1995||Aug 11, 1998||Hoffmann-La Roche Inc.||Polyethylene-protein conjugates|
|US5834594 *||Jun 1, 1995||Nov 10, 1998||Hoffman-La Roche Inc.||Polyethylene-protein conjugates|
|US5849860 *||Jun 1, 1995||Dec 15, 1998||Hoffmann-La Roche Inc.||Polyethylene-protein conjugates|
|US8617863||Jun 3, 2009||Dec 31, 2013||Grifols Therapeutics Inc.||Composition, method, and kit for preparing plasmin|
|WO1993020838A1 *||Apr 15, 1993||Oct 28, 1993||Rufeld Inc||Method and compositions for treatment of pyonecrotic processes|
|U.S. Classification||435/178, 424/94.3, 424/94.64, 435/181|
|International Classification||A61K38/16, C12N11/00, C12N11/10|
|Cooperative Classification||C12N11/10, A61K38/166|
|European Classification||C12N11/10, A61K38/16B1|